The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The adverse event profile of pregabalin: A systematic review and meta‐analysis of randomized controlled trials
Abstract
Summary: Purpose: Despite the widespread use of antiepileptic drugs (AEDs) across different neurologic and psychiatric disorders, no study has systematically reviewed all available randomized controlled trials (RCTs) of a given AED to fully uncover its tolerability profile. We aimed at identifying treatment emergent adverse events (AEs) associated with pregabalin through a systematic review and meta‐analysis of all available RCTs. We also assessed the association between serious AEs and pregabalin, and investigated whether pregabalin AEs display a dose–response relationship. Methods: We searched MEDLINE, EMBASE, and Cochrane CENTRAL to February 2010 for RCTs. Additional studies were identified from reference lists of retrieved papers and from online clinical databases. We selected placebo‐controlled, double‐blind RCTs investigating the therapeutic effects of pregabalin in adults with any condition. Studies had to include at least 20 subjects per arm and have a duration of at least 4 weeks. AEs were assessed for their association with pregabalin after identification/exclusion of synonyms, rare AEs, and nonassessable AEs due to methodologic limitations. We used relative risks (RRs) to assess the association of any [99% confidence intervals (CIs)] or serious AEs (95% CIs) with pregabalin, and risk differences (RDs, 95% CIs) to investigate dose–response relationships of pregabalin AEs. Key findings: Thirty‐eight RCTs were included in our study. Of 39 AEs, 20 (51%) were significantly associated with pregabalin (dizziness, vertigo, incoordination, balance disorder, ataxia, diplopia, blurred vision, amblyopia, tremor, somnolence, confusional state, disturbance in attention, thinking abnormal, euphoria, asthenia, fatigue, edema, peripheral edema, dry mouth, constipation). The highest RRs were found for cognition/coordination AEs. There was no significant association between serious AEs and pregabalin. There was a selective dose–response pattern in the onset of pregabalin AEs, with certain AEs appearing at lower doses than others. Significance: Individuals starting treatment with pregabalin are at increased risk for several AEs, particularly those affecting cognition/coordination. Pregabalin AEs appear according to a selective dose–response pattern, possibly reflecting the severity of dysfunction of distinct anatomic structures. These findings may aid clinicians in providing better patient management, and support the value of including in meta‐analyses of AED tolerability profiles RCTs performed in different conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Johannessen Landmark, C. (2008) · CNS Drugs · doi:10.2165/00023210-200822010-00003 · Cited by 316
Arnold, L. M., Russell, I. J., Diri, E. W., Duan, W. R., Young, J. P., Sharma, U., Martin, S. A., Barrett, J. A., & Haig, G. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2008.03.013 · Cited by 277
Crofford, L. J., Mease, P. J., Simpson, S. L., Young, J. P., Martin, S. A., Haig, G. M., & Sharma, U. (2008) · Pain · doi:10.1016/j.pain.2008.02.027 · Cited by 236
Pande, A. C., Feltner, D. E., Jefferson, J. W., Davidson, J. R. T., Pollack, M., Stein, M. B., Lydiard, R. B., Futterer, R., Robinson, P., Slomkowski, M., et al. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117423.05703.e7 · Cited by 227
Research works printed but not linked: 57
- 10.1186/1471-2377-8-33 · DOI · Paper page
- 10.1111/j.1526-4637.2007.00332.x · DOI
- 10.1111/j.0013-9580.2004.31203.x · doi:10.1111/j.0013-9580.2004.31203.x
- 10.1111/j.0013-9580.2004.455003.x · DOI · Paper page
- 10.1212/01.WNL.0000150932.48688.BE · doi:10.1212/01.wnl.0000150932.48688.be
- Chadwick DW, 2000, Zonisamide for drug‐resistant partial epilepsy, Cochrane Database Syst Rev, 2
- Chadwick DW, 2002, Zonisamide add‐on for drug‐resistant partial epilepsy, Cochrane Database Syst Rev, 4, CD001416
- Chadwick DW, 2005, Zonisamide add‐on for drug‐resistant partial epilepsy, Cochrane Database Syst Rev, 4, CD001416
- Chaisewikul R, 2001, Levetiracetam add‐on for drug‐resistant localization related (partial) epilepsy, Cochrane Database Syst Rev, 1, CD001901
- 10.1002/art.20983 · DOI · Paper page
- de Haas S, 2007, Exploratory polysomnographic evaluation of pregabalin on sleep disturbance in patients with epilepsy, J Clin Sleep Med, 3, 473, 10.5664/jcsm.26911 · DOI
- 10.1212/01.WNL.0000055433.55136.55 · DOI · Paper page
- 10.1111/j.1528-1167.2005.00341.x · doi:10.1111/j.1528-1167.2005.00341.x
- 10.1097/01.jcp.0000084032.22282.ff · DOI · Paper page
- 10.1097/YIC.0b013e3282f0f0d7 · DOI
- 10.1016/j.jns.2009.06.044 · DOI
- 10.1212/01.WNL.0000068024.20285.65 · DOI · Paper page
- 10.1016/j.pain.2005.02.032 · DOI · Paper page
- Hemming K, 2008, Vigabatrin for refractory partial epilepsy, Cochrane Database Syst Rev, 3, CD007302
- 10.1136/gut.2006.110858 · DOI · Paper page
- Jette NJ, 2000, Topiramate for drug‐resistant partial epilepsy, Cochrane Database Syst Rev, 2, CD001417
- Jette NJ, 2002, Topiramate add‐on for drug‐resistant partial epilepsy, Cochrane Database Syst Rev, 3, CD001417
- Jette N, 2008, Topiramate add‐on for drug‐resistant partial epilepsy, Cochrane Database Syst Rev, 3, CD001417
- 10.1097/YIC.0b013e32831d7980 · DOI
- Leach JP, 2002, Remacemide for drug‐resistant localization related epilepsy, Cochrane Database Syst Rev, 4, CD001900
- 10.1111/j.1528-1167.2008.01954.x · doi:10.1111/j.1528-1167.2008.01954.x
- 10.1212/01.WNL.0000145767.36287.A1 · DOI · Paper page
- 10.1073/pnas.0710771105 · DOI
- Lozsadi D, 2008, Pregabalin add‐on for drug‐resistant partial epilepsy, Cochrane Database Syst Rev, 1, CD005612
- 10.1111/j.1528-1157.1997.tb01251.x · DOI · Paper page
- Marson AG, 2000, Gabapentin for drug‐resistant partial epilepsy, Cochrane Database Syst Rev, 2, CD001415
- 10.1016/S0920-1211(01)00287-X · DOI
- Mease PJ, 2008, A randomized, double‐blind, placebo‐controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia, J Rheumatol, 35, 502
- Michael B, 2008, Clobazam as an add‐on in the management of refractory epilepsy, Cochrane Database Syst Rev, 2, CD004154
- 10.4088/JCP.v67n0511 · DOI · Paper page
- 10.1192/bjp.bp.107.037788 · DOI
- 10.1016/j.bbr.2009.11.042 · DOI
- 10.1176/appi.ajp.160.3.533 · DOI · Paper page
- Pereira J, 2002, Tiagabine add‐on for drug‐resistant partial epilepsy, Cochrane Database Syst Rev, 3, CD001908
- 10.1212/01.wnl.0000345667.45642.61 · DOI · Paper page
- 10.1097/01.jcp.0000155820.74832.b0 · DOI · Paper page
- Ramaratnam S, 2000, Lamotrigine add‐on for drug‐resistant partial epilepsy, Cochrane Database Syst Rev, 3
- RevMan, 2008, Review Manager (RevMan) [Computer program]. Version 5.0
- 10.1016/j.jpain.2004.12.007 · DOI · Paper page
- 10.1001/archpsyc.62.9.1022 · DOI · Paper page
- 10.1017/S1092852900015571 · DOI
- 10.1016/j.pain.2004.05.001 · DOI · Paper page
- 10.2147/NDT.S4716 · doi:10.2147/ndt.s4716
- 10.1111/j.1468-1331.2009.02916.x · DOI
- 10.1016/j.pain.2004.01.001 · DOI · Paper page
- 10.1212/01.wnl.0000244422.45278.ff · DOI · Paper page
- 10.1016/j.jpain.2008.05.014 · DOI
- 10.1016/j.ejpain.2007.05.003 · DOI · Paper page
- 10.1185/030079906X80404 · DOI · Paper page
- 10.1016/j.pain.2007.06.033 · DOI · Paper page
- Zesiewicz TA, 2007, A pilot, double‐blind, placebo‐controlled trial of pregabalin (Lyrica) in the treatment of essential tremor, Mov Disord, 22, 1661
- 10.1038/ng0197-62 · DOI · Paper page
Cited by
Abuse and Misuse of Pregabalin and Gabapentin
Evoy, K. E., Morrison, M. D., & Saklad, S. R. (2017) · Drugs · doi:10.1007/s40265-017-0700-x · Cited by 410
Skvarc, D. R., Berk, M., Byrne, L. K., Dean, O. M., Dodd, S., Lewis, M., Marriott, A., Moore, E. M., Morris, G., Page, R. S., et al. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.11.011 · Cited by 312
Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews
Wiffen, P. J., Derry, S., Moore, R. A., Aldington, D., Cole, P., Rice, A. S., Lunn, M. P., Hamunen, K., Haanpaa, M., & Kalso, E. A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010567.pub2 · Cited by 306
Stahl, S. M., Porreca, F., Taylor, C. P., Cheung, R., Thorpe, A. J., & Clair, A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.001 · Cited by 277
O'Connell, N. E., Wand, B. M., McAuley, J. H., Marston, L., & Moseley, G. L. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009416.pub2 · Cited by 244
Metadata
- Authors
- Zaccara, G., Gangemi, P., Perucca, P., & Specchio, L.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2011-02-14
- Volume
- 52
- Issue
- 4
- Pages
- 826-836
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W1965579959
- Cited by
- 216
- References
- 4
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The adverse event profile of pregabalin: A systematic review and meta‐analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1111/j.1528-1167.2010.02966.x
- The paper
- Zaccara, G., Gangemi, P., Perucca, P., & Specchio, L. (2011). The adverse event profile of pregabalin: A systematic review and meta‐analysis of randomized controlled trials. Epilepsia. https://doi.org/10.1111/j.1528-1167.2010.02966.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.